

BIOCON GROUP

FACT SHEET

September - 2019

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET		
	(Rs Cr)	
	September 30, 2019	March 31, 2019
ASSETS		
Non-current assets		
(a) Property, plant and equipment	4,414	4,253
(b) Capital work-in-progress	1,734	1,287
(c) Right-of-use assets	134	-
(d) Goodwill	26	26
(e) Other intangible assets	208	192
(f) Intangible assets under development	761	612
(g) Investments in associates and a joint venture	26	43
(h) Financial assets		
Investments	402	139
Derivative assets	59	71
Other financial assets	35	39
(i) Income-tax asset, net	169	169
(j) Deferred tax asset, net	308	325
(k) Other non-current assets	243	213
	8,519	7,370
Current assets		
(a) Inventories	1,341	1,032
(b) Financial assets		
Investments	559	829
Trade receivables	1,112	1,292
Cash and cash equivalents	655	730
Other bank balances	131	327
Derivative assets	71	78
Other financial assets	562	387
(c) Other current assets	178	149
	4,610	4,823
TOTAL	13,128	12,192
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	600	300
(b) Other equity	5,781	5,798
Equity attributable to owners of the Company	6,381	6,098
Non-controlling interests	645	609
	7,026	6,707
Non-current liabilities		
(a) Financial liabilities		
Borrowings	1,684	1,526
Lease liabilities	85	15
Derivative liability	71	35
(b) Provisions	83	66
(c) Other non-current liabilities	823	805
	2,746	2,447
Current liabilities		
(a) Financial liabilities		
Borrowings	459	261
Lease liabilities	6	1
Trade payables	1,266	1,198
Derivative liability	12	14
Other financial liabilities	1,085	991
(b) Provisions	97	81
(c) Income tax liability, net	156	124
(d) Other current liabilities	276	369
	3,357	3,039
TOTAL	13,128	12,192

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	H1 FY 2020	H1 FY 2019	Variance
INCOME			
Small molecules	1,009	832	21%
Biologics	1,006	617	63%
Branded formulations	262	311	-16%
Research services	886	825	7%
Inter-segment	(124)	(140)	-12%
Revenue from operations #	3,038	2,445	24%
Other income	63	123	-49%
TOTAL REVENUE	3,101	2,568	21%
EXPENDITURE			
Material & Power costs	1,040	998	4%
Staff costs	631	500	26%
Research & Development expenses*	183	121	51%
Other expenses	343	249	38%
Manufacturing, staff & other expenses	2,198	1,867	18%
EBITDA	903	701	29%
Interest & Finance charges	31	36	-16%
Depreciation & Amortisation	256	211	21%
Share of loss / (profit) in JV / Associate, net	17	0	4225%
PBT BEFORE EXCEPTIONAL ITEM	599	453	32%
Exceptional item, Net	68	189	-
PBT	667	641	4%
Taxes	142	107	32%
Taxes on exceptional item	44	18	-
NET PROFIT BEFORE MINORITY INTEREST	482	516	-7%
Minority interest	46	42	10%
Minority interest on exceptional item	14	-	-
NET PROFIT FOR THE PERIOD	422	474	-11%
EPS Rs.	3.5	4.0	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	412	304	36%
Exceptional item, net of taxes	10	171	
NET PROFIT FOR THE PERIOD	422	474	-11%
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	14	11	
* Gross Research & Development expenses	233	208	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q2 FY 20	Q2 FY 19	Variance
INCOME			
Small molecules	530	432	23%
Biologics	516	368	40%
Branded formulations	128	164	-22%
Research services	465	419	11%
Inter-segment	(66)	(61)	9%
Revenue from operations #	1,572	1,322	19%
Other income	38	54	-29%
TOTAL REVENUE	1,611	1,376	17%
EXPENDITURE			
Material & Power costs	549	506	8%
Staff costs	322	264	22%
Research & Development expenses*	104	77	36%
Other expenses	194	135	44%
Manufacturing, staff & other expenses	1,169	982	19%
EBITDA	441	394	12%
Interest & Finance charges	14	19	-26%
Depreciation & Amortisation	132	112	17%
Share of loss / (profit) in JV / Associate, net	9	1	944%
PBT BEFORE EXCEPTIONAL ITEM	286	262	9%
Exceptional item, Net	68	189	-64%
PBT	354	451	-22%
Taxes	73	55	33%
Taxes on exceptional item	27	18	-
NET PROFIT BEFORE MINORITY INTEREST	254	378	-33%
Minority interest	24	23	6%
Minority interest on exceptional item	14	-	
NET PROFIT FOR THE PERIOD	216	355	-39%
EPS Rs.	1.8	3.0	
NET PROFIT BEFORE EXCEPTIONAL ITEM	189	184	3%
Exceptional item, net of taxes	27	171	
NET PROFIT FOR THE PERIOD	216	355	-39%
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	7	5	
* Gross Research & Development expenses	123	88	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q2 FY 20	Q1 FY 20	Variance
INCOME			
Small molecules	530	480	10%
Biologics	516	490	5%
Branded formulations	128	133	-4%
Research services	465	421	10%
Inter-segment	(66)	(58)	15%
Revenue from operations #	1,572	1,466	7%
Other income	38	24	59%
TOTAL REVENUE	1,611	1,490	8%
EXPENDITURE			
Material & Power costs	549	491	12%
Staff costs	322	309	4%
Research & Development expenses*	104	79	33%
Other expenses	194	149	30%
Manufacturing, staff & other expenses	1,169	1,028	14%
EBITDA	441	462	-4%
Interest & Finance charges	14	17	-16%
Depreciation & Amortisation	132	124	6%
Share of loss / (profit) in JV / Associate, net	9	8	19%
PBT BEFORE EXCEPTIONAL ITEM	286	313	-8%
Exceptional item, Net	68	-	-
PBT	354	313	13%
Taxes	73	69	7%
Taxes on exceptional item	27	17	62%
NET PROFIT BEFORE MINORITY INTEREST	254	228	11%
Minority interest	24	21	14%
Minority interest on exceptional item	14	-	-
NET PROFIT FOR THE PERIOD	216	206	5%
EPS Rs.	1.8	1.7	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	189	223	-15%
Exceptional item, net of taxes	27	(17)	
NET PROFIT FOR THE PERIOD	216	206	5%
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	7	7	
* Gross Research & Development expenses	123	110	